GSK lung cancer drug Jemperli to advance to phase 3 study
(Alliance News) - GSK PLC on Wednesday said its drug for metastatic non-squamous non-small cell lung cancer Jemperli, or dostarlimab, is advancing to a phase 3 trial following positive results. Read More